Know Cancer

forgot password

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

Phase 2
15 Years
Open (Enrolling)
Chemotherapy-Induced Nausea and Vomiting

Thank you

Trial Information

Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

OUTLINE: This is a multi-center study.

Treatment Regimen:

Patients must have no nausea and/or vomiting for 24 hours and must not have used other
anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start
until this criteria is satisfied.

Any germ cell chemotherapy regimen utilizing cisplatin (20mg/m2 x 5 days). This will usually
be combined with bleomycin (BEP), etoposide (EP), ifosfamide (VIP), vinblastine (VeIP),
paclitaxel (TIP) or epirubicin. All of these regimens get the identical cisplatin, which is
the only highly emetic drug in any of the chemo regimens.

Acute emesis prophylaxis (administered per institutional standards prior to chemotherapy):

- Any 5HT3 receptor antagonist may be used days 1 through 5 or days 1, 3 and 5 if
palonosetron is used per institutional standards.

- Dexamethasone 20mg PO (orally) daily, days 1 and 2

- Fosaprepitant 150mg IV on day 3

Delayed emesis prophylaxis:

- Fosaprepitant 150mg IV on day 5

- Dexamethasone 4mg PO BID (twice a day) on days 6, 7 and 8

PRN (as needed) antiemetics allowed at the discretion of the treating investigator

- No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will
be given during the acute or delayed treatment periods

ECOG Performance Status of 0-2

Life Expectancy: Not specified


- White blood cell count (WBC) > 3.0 K/mm3

- Absolute neutrophil count ≥ 1.5 K/mm3

- Hemoglobin (Hgb) > 10 g/dL

- Platelets > 100 K/mm3


- Bilirubin < 1.5 x ULN (upper limit of normal)

- Aspartate aminotransferase (AST, SGOT) ≤ 3 x ULN

- Alanine aminotransferase (ALT, SGPT) ≤ 3 x ULN


- Creatinine ≤ 2 mg/dl

Inclusion Criteria:

- Male patients ≥15 years of age with histologically or cytologically confirmed
diagnosis of germ cell tumor receiving a standard 5 day cisplatin based chemotherapy
regimen. Prior chemotherapy is allowed. Patients do not have to be chemo naïve.

- Written informed consent and HIPAA authorization for release of personal health

- Patients must have had no nausea or vomiting for 24 hours and no anti-emetic use for
72 hours prior to starting protocol therapy. Treatment must not start in registered
patients until this criteria is met.

Exclusion Criteria:

- No active central nervous system (CNS) metastases. Patients with neurological
symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis. NOTE:
A patient with prior brain metastasis may be considered if they have completed their
treatment for brain metastasis, no longer require corticosteroids, and are

- No prior malignancy is allowed except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, Gleason < grade 7 prostate cancers, or
other cancer for which the patient has been disease-free for at least 1 year.

- No previous treatment with any investigational agent within 30 days prior to
registration for protocol therapy.

- No concurrent participation in a clinical trial which involves another
investigational agent.

- No use of agents expected to induce the metabolism of fosaprepitant which include:
rifampin, rifabutin, phenytoin, carbamazepine, and barbiturates.

- No concurrent use of agents which may inhibit metabolism of fosaprepitant which
include: cisapride, macrolide antibiotics (erythromycin, clarithromycin,
azithromycin), azole antifungal agents (ketoconazole, itraconazole, voriconazole,
fluconazole), amifostine, nelfinavir, calcium channel antagonists such as verapamil
and diltiazem, and ritonavir.

- No concurrent use of warfarin while on study.

- No known history of anticipatory nausea or vomiting.

- No clinically significant infections as judged by the treating investigator.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the Complete Response (CR) Rate of No Emetic Episodes or Use of Rescue Medications

Outcome Description:

This will determine the Complete Response (CR) rate (no emetic episodes or use of rescue medications) in germ cell tumor patients treated with IV fosaprepitant in combination with a 5HT3RA plus dexamethasone during a 5 day cisplatin regimen

Outcome Time Frame:

1 month

Safety Issue:


Principal Investigator

Lawrence Einhorn, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Hoosier Oncology Group


United States: Institutional Review Board

Study ID:




Start Date:

January 2013

Completion Date:

January 2015

Related Keywords:

  • Chemotherapy-Induced Nausea and Vomiting
  • Fosaprepitant
  • 5HT3 Receptor Antagonists
  • Dexamethasone
  • Germ Cell Tumors
  • Testis Cancer
  • Rescue Medications
  • Vomiting
  • Neoplasms, Germ Cell and Embryonal



Indiana University Melvin and Bren Simon Cancer CenterIndianapolis, Indiana  46202-5289
Siteman Cancer CenterSaint Louis, Missouri  63110
MUSC Hollings Cancer CenterCharleston, South Carolina  29425